Fig. 4From: Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysisSummary of the secondary safety outcomes. Network plot of (A) The forest plot for serious adverse events; (B) The SUCRA value of each treatment for serious adverse events. SUCRA: surface under the cumulative ranking curveBack to article page